Top

Published in:

01-08-2012 | Original Article

Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm

Authors: Ajinkya B. Yele, Nikhil D. Thawal, Praveen K. Sahu, Balu A. Chopade

Published in: Archives of Virology | Issue 8/2012

Abstract

Acinetobacter baumannii infections are difficult to treat due to biofilm formation. The literature shows paucity of data on A. baumannii bacteriophages and their application in biofilm control. In this report, we have isolated a new lytic bacteriophage, AB7-IBB1, infecting A. baumannii. Transmission electron microscopy revealed its resemblance to members of the family Siphoviridae, with a tail size of 240 × 10 nm and an icosahedral head 50 nm in diameter. Plaques were 3-5 mm in diameter after 24 h, increasing to 7-9 mm in three days. The phage genome size was determined to be ~75 kb. AB7-IBB1 could lyse 23 of 39 (59 %) clinical isolates of A. baumannii. It exhibited rapid adsorption (>99 % adsorbed in 5 min), a latency period of 30 min and a burst size of 125 PFU/infected cell. The phage affected A. baumannii biofilm formation on an abiotic surface (polystyrene) and a biotic surface (human embryonic kidney 293 cell line). It also showed biofilm control ability on an abiotic surface (polystyrene). FESEM visualization studies confirmed the detrimental effect of phage AB7-IBB1 on host biofilm. In conclusion, this study reports a novel lytic bacteriophage, AB7-IBB1, belonging to family Siphoviridae, with promising anti-biofilm properties.

Ackermann HW (2009) Basic phage electron microscopy. In: Clokie MRJ, Kropinski AM (eds) Bacteriophages: methods and protocols, vol 1., Isolation, characterization, and interactions. Humana Press, New York, pp 113–126CrossRef

Ackermann HW, Brochu G, Emadi Konjin HP (1994) Classification of Acinetobacter phages. Arch Virol 135:345–354PubMedCrossRef

Adams MH (1959) Bacteriophages. Interscience Publishers Inc, New York

Ahiwale S, Tamboli N, Thorat K, Kulkarni R, Ackermann H, Kapadnis B (2011) In vitro management of hospital Pseudomonas aeruginosa biofilm using indigenous T7-like lytic phage. Curr Microbiol 62:335–340PubMedCrossRef

Alisky J, Iczkowski K, Rapoport A, Troitsky N (1998) Bacteriophages show promise as antimicrobial agents. J Infect 36:5–15PubMedCrossRef

Augustin M, Ali-vehmas T, Atroshi F (2004) Assessment of enzymatic cleaning agents and disinfectants against bacterial biofilms. J Pharm Pharmaceut Sci 7(1):55–64

Boulanger (2009) Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles. In: Clokie MRJ, Kropinski AM (eds) Bacteriophages: methods and protocols, vol 2., Molecular and applied aspects. Humana Press, New York, pp 227–238CrossRef

Catalano M, Quelle LS, Jeric PE, Di Martino A, Maimone SM (1999) Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect 42:27–35PubMedCrossRef

Cerqueira GM, Peleg AY (2011) Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. doi:10.1002/iub.533 PubMed

10.

Davies D (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114–122PubMedCrossRef

11.

Deshpande LM, Chopade BA (1994) Plasmid mediated silver resistance in Acinetobacter baumannii. Biometals 7:49–56PubMedCrossRef

12.

Dhakephalkar PK, Chopade BA (1994) High levels of multiple metal resistances and its correlation to antibiotic resistance in environmental isolates of Acinetobacter. Biometals 7:67–74PubMedCrossRef

13.

Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Micro 5:939–951CrossRef

14.

Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15(2):167–193PubMedCrossRef

15.

Doolittle MM, Cooney JJ, Caldwell DE (1995) Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can J Microbiol 41(1):12–18PubMedCrossRef

16.

Doolittle MM, Cooney JJ, Caldwell DE (1996) Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Ind Microbiol 16(6):331–341PubMedCrossRef

17.

Dusane DH, Rajput JK, Kumar AR, Nancharaiah YV, Venugopalan VP, Zinjarde SS (2008) Disruption of fungal and bacterial biofilms by lauroyl glucose. Lett Appl Microbiol 47(5):374–379PubMedCrossRef

18.

Hsieh SE, Lo HH, Chen ST, Lee MC, Tseng YH (2010) Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol 77(3):756. doi:10.1128/AEM.01848-10 PubMedCrossRef

19.

Joly-Guillou ML (2005) Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 11:868–873PubMedCrossRef

20.

Juda M, Paprota K, Jałoza D, Malm A, Rybojad P, Goździuk K (2008) EDTA as a potential agent preventing formation of Staphylococcus epidermidis biofilm on polichloride vinyl biomaterials. Ann Agric Environ Med 15(2):237–241PubMed

21.

Knezevic P, Petrovic O (2008) A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. J Microbiol Methods 74:114–118PubMedCrossRef

22.

Kwiatek M, Parasion S, Mizak L, Gryko R, Bartoszcze M, Kocik J (2011) Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains. Arch Virol. doi:10.1007/s00705-011-1160-3 PubMed

23.

Lee CN, Tseng TT, Lin JW, Fu YC, Weng SF, Tseng YH (2011) Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumannii and phage phiKO2. Appl Environ Microbiol 77(19):6755–6762PubMedCrossRef

24.

Lin NT, Chiou PY, Chang KC, Chen LK, Lai MG (2010) Isolation and characterization of ΦAB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol 161(4):308–314PubMedCrossRef

25.

Linghor E, Frost S, Johnson RP (2009) Determination of bacteriophage genome size by pulsed field gel electrophoresis (PFGE). In: Clokie MRJ, Kropinski AM (eds) Bacteriophages: methods and protocols, vol 2., Molecular and applied aspects. Humana Press, New York, pp 19–25CrossRef

26.

Moreira CG, Palmer K, Whiteley M et al (2006) Bundle-forming pili and EspA are involved in biofilm formation by enteropathogenic Escherichia coli. J Bacteriol 188(11):3952–3961PubMedCrossRef

27.

Musk DJ, Banko DA, Hergenrother PJ (2005) Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem Biol 12(7):789–796PubMedCrossRef

28.

Pardesi KR (2008) Role of plasmids in spread of antibiotic resistance in Acinetobacter species, isolated from healthy human skin and clinical specimens. Ph. D Thesis, University of Pune

29.

Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA (2008) A study on nosocomial pathogens in ICU with special reference to multi-resistant Acinetobacter baumannii harbouring multiple plasmids. Indian J Med Res 128:178–187PubMed

30.

Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582PubMedCrossRef

31.

Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS, Chopade BA (2011) Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol 62(3):328–338PubMedCrossRef

32.

Prigent-Combaret C, Vidal O, Dorel C, Lejeune P (1999) Abiotic surface sensing and biofilm-dependent regulation of gene expression in Escherichia coli. J Bacteriol 181(19):5993–6002PubMed

33.

Rodrigues L, van der Mei HC, Teixeira J, Oliveira R (2004) Influence of biosurfactants from probiotic bacteria on formation of biofilms on voice prostheses. Appl Environ Microbiol 70(7):4408–4441PubMedCrossRef

34.

Sahu PK, Iyer PS, Gaikwad MB, Talreja SC, Pardesi KR, Chopade BA (2012) An MFS transporter-like ORF from MDR Acinetobacter baumannii AIIMS 7 is associated with adherence and biofilm formation on biotic/abiotic surface. Int J Microbiol 2012:490647. doi:10.1155/2012/490647 PubMed

35.

Shakibaie MR, Dhakephalkar PK, Kapadnis BP, Salayaghe G, Chopade BA (1998) Plasmid mediated silver and antibiotic resistance in Acinetobacter baumannii BL54. Iranian J Med Sc 23(12):30–36

36.

Sillankorva S, Neubauer P, Azeredo J (2008) Pseudomonas fluorescens biofilms subjected to phage phiIBB-PF7A. BMC Biotechnol 8:79. http://www.biomedcentral.com/1472-6750/8/79

37.

Soothill JS (1992) Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37(4):258–261PubMedCrossRef

38.

Stenholm AR, Dalsgaard I, Middelboe M (2008) Isolation and characterization of bacteriophages infecting the fish pathogen Flavobacterioum psychrophilum. Appl Environ Microbiol 74(13):4070–4078PubMedCrossRef

39.

Sutherland IW, Hughes KA, Skillman LC, Tait K (2004) The interaction of phage and biofilms. FEMS Microbiol Lett 232(1):1–6PubMedCrossRef

40.

Tait K, Sutherland IW (2002) Antagonistic interactions amongst bacteriocin-producing enteric bacteria in dual species biofilms. J Appl Microbiol 93(2):345–352PubMedCrossRef

41.

Towner KJ, Chopade BA (1987) Biotyping of Acinetobacter calcoaceticus using the API 2ONE system. J Hosp Infect 10(2):145–151PubMedCrossRef

42.

Watnick P, Kolter R (2000) Biofilm, city of microbes. J Bacteriol 182(10):2675–2679PubMedCrossRef

43.

Yang H, Liang L, Lin S, Jia S (2010) Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC microbiol 10:131. http://www.biomedcentral.com/1471-2180/10/131

Title: Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm
Authors: Ajinkya B. Yele
Nikhil D. Thawal
Praveen K. Sahu
Balu A. Chopade
Publication date: 01-08-2012
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 8/2012
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-012-1320-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

In vitro and in vivo evaluation of a novel antiherpetic flavonoid, 4′-phenylflavone, and its synergistic actions with acyclovir

Molecular prevalence of bovine noroviruses and neboviruses detected in central-eastern Tunisia

Antigen capture ELISA system for henipaviruses using polyclonal antibodies obtained by DNA immunization

Isolation of Newcastle disease virus from a non-avian host (sheep) and its implications

Discovery and genetic characterization of novel caliciviruses in German and Dutch poultry

Phylogeographic analysis of avian influenza viruses isolated from Charadriiformes in Belgium confirms intercontinental reassortment in gulls

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials